Retina Eye Center

02/03/2026

February is Age-Related Macular Degeneration and Low Vision Awareness Month - a time to spotlight the leading cause of vision loss in adults over 50. AMD affects the retina and can make everyday tasks like reading or seeing faces more difficult. Early diagnosis and regular eye exams are key to protecting your vision. Learn more: https://brnw.ch/21wZCTB

01/29/2026

Ocular Therapeutix is moving forward with plans to seek FDA approval for AXPAXLI, a potential new treatment for wet age-related macular degeneration (wet AMD). Backed by encouraging results from a phase 3 clinical trial, AXPAXLI could offer a new option for patients by helping maintain vision with fewer injections. Learn more: https://brnw.ch/21wZuGu

Ocular Therapeutix accelerates NDA plans for AXPAXLI, targeting wet AMD treatment, following promising phase 3 trial results.

01/27/2026

Kiora Pharmaceuticals has received a new patent for KIO-104, a potential non-steroidal treatment for retinal inflammation. Unlike traditional steroids, KIO-104 targets inflammation at the cellular level and is being tested in a Phase 2 trial for conditions like non-infectious uveitis and diabetic macular edema. This innovation may offer new hope for patients with inflammatory eye diseases. Learn more: https://brnw.ch/21wZrr6

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.

01/22/2026

Macular holes and macular puckers affect the macula, the part of the retina responsible for sharp central vision. They can cause blurred or distorted vision and make everyday tasks like reading or recognizing faces more difficult. Many cases only need monitoring, but surgery is an option when vision loss begins to impact quality of life. Learn more: https://brnw.ch/21wZjww

01/20/2026

Ocular Therapeutix has started a phase 3 clinical trial to test a new treatment called AXPAXLI for non-proliferative diabetic retinopathy (NPDR), a common cause of vision loss in people with diabetes. This one-time, long-lasting treatment could reduce the need for frequent eye injections and help more patients protect their sight. Learn more: https://brnw.ch/21wZf3i

HELIOS-3 is a phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

01/15/2026

Your retina plays a vital role in how you see by sending images to your brain. At The Retina Eye Center, we use advanced technology to diagnose and treat a wide range of retinal, macular, and vitreous conditions with personalized care focused on protecting your vision. Learn more: https://brnw.ch/21wZ7vY

01/13/2026

A new treatment for wet age-related macular degeneration may be one step closer. Ocular Therapeutix plans to move faster toward FDA review of AXPAXLI after positive results from a large clinical trial showed it helped maintain vision when compared to current standard treatments. Learn more about this potential advancement and what it could mean for patients with wet AMD: https://brnw.ch/21wZ3OK

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

01/08/2026

Diagnosed with diabetes? Your eyes need attention, too. High blood sugar can quietly damage the retina, but early exams and good diabetes management can go a long way in protecting your vision. Learn more: https://brnw.ch/21wYVCf

01/06/2026

Starting care with us in 2026? Your first retina exam will be detailed and may take 2 to 3 hours, including dilation. Please bring your ID, medical insurance card (not vision), a list of medications, completed forms, and a driver for after your visit. Learn more: https://brnw.ch/21wYS4b

01/01/2026

Wishing everyone a bright and healthy New Year filled with clear vision and new beginnings. Thank you for trusting us with your eye care - we look forward to seeing you in 2026!

12/30/2025

Opus Genetics has treated the first patient in a new gene therapy trial for Best disease, a rare inherited condition that causes vision loss. This one-time treatment aims to replace the faulty BEST1 gene and protect retinal function, marking a promising step forward for patients and families. Learn more: https://brnw.ch/21wYJDc

Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and potentially blindness.

12/23/2025

Cataract surgery is one of the most successful eye procedures, but it can occasionally impact the retina. If you notice new floaters, flashes, or blurry vision after surgery, it’s important to get checked. Read our blog to learn more: https://brnw.ch/21wYAtn